Our results in 2 rapidly progressive Pkd1 mouse models strongly support senicapoc’s ability to delay early-stage increases in renal cyst number and fibrosis with only 5 days’ treatment and its ability to slow cyst enlargement and fibrosis over a 10-day treatment course. This evidence concerns the gene PKD1 and cystic kidney disease.